Physician Assistant Program year 2025 Source: CMS Open Payments, 2026 publication

Pamela Hassler

Physician Assistant Reno, NV Physician Assistant

NPI 1841411212 CMS profile 11159335

605 Sierra Rose Dr, Ste 4, Reno, NV 89511

Open in the dashboard

General payments

$1,866

53 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Pamela Hassler of Reno, NV is reported in the CMS Open Payments database as having received $1,866 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $1,866 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pamela Hassler
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Pamela Hassler were reported at $1,866. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Pamela Hassler Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $0 $167 $52–$557 $160
2024 $0 $178 $55–$600 $164
2025 $1,866 $184 $57–$620 $169

Breakdown

Who paid General payments · program year 2025
  1. Medtronic, Inc. $1,120 25 payments
  2. Boston Scientific Corporation $209 4 payments
  3. Nalu Medical, Inc. $164 6 payments
  4. TerSera Therapeutics LLC $100 4 payments
  5. Vertex Pharmaceuticals Incorporated $96 4 payments
  6. AbbVie, Inc. $61 4 payments
  7. Averitas Pharma Inc. $30 2 payments
  8. Globus Medical, Inc. $28 1 payment
  9. Collegium Pharmaceutical, Inc. $22 1 payment
  10. Abbott Laboratories $19 1 payment
  11. Other $18 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $1,037 34 payments
  2. Travel and Lodging $739 17 payments
  3. Education $90 2 payments
Products named General payments · program year 2025
  1. INTELLIS ADAPTIVESTIM $1,067 21 payments
  2. General - Pain Management $209 4 payments
  3. Nalu Neurostimulation System $164 6 payments
  4. Prialt $100 4 payments
  5. JOURNAVX $96 4 payments
  6. QULIPTA $61 4 payments
  7. SYNCHROMEDII $53 4 payments
  8. UBRELVY $46 3 payments
  9. Qutenza $30 2 payments
  10. Senza $28 1 payment
  11. Other $58 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

782

Median for Physician Assistant: 241

Drug cost

$35,599

Median for Physician Assistant: $4,110

Branded share of claims

14.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 12 $17,043
Linzess Linaclotide Brand 13 $7,481
Carbamazepine Er Carbamazepine Brand 14 $1,173
Levothyroxine Sodium Generic 86 $918
Albuterol Sulfate Hfa Albuterol Sulfate Brand 30 $693
Potassium Chloride Generic 14 $654
Duloxetine Hcl Generic 27 $652
Atorvastatin Calcium Generic 65 $619
Omeprazole Generic 48 $552
Gabapentin Generic 28 $545

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$10,872

Medicare's payments for the services billed

Medicare patients

95

Average age 76

Services billed

400

61 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 40%
Chronic kidney disease 38%
Atrial fibrillation 34%
Heart failure 29%
Diabetes 28%
Ischemic heart disease 24%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record